Bioventus BVS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Net Sales by Business | |||||
| International Segment | $65.99M-0.7% | $66.47M+6.4% | $62.49M+9.9% | $56.87M— | |
| U.S. Segment | $502.1M-0.9% | $506.81M+12.7% | $449.86M-1.2% | $455.25M— | |
| Total Net Sales by Product | |||||
| Pain Treatments | $279.06M+6.8% | $261.29M+18.3% | $220.8M+2.1% | $216.33M-2.4% | |
| Restorative Therapies | $85.37M-30.4% | $122.74M-5.5% | $129.94M-11.9% | $147.51M+21.3% | |
| Surgical Solutions | $203.65M+7.6% | $189.26M+17.1% | $161.6M+9.0% | $148.28M+69.0% | |
| Total Net Sales by Geography | |||||
| International | $65.99M-0.7% | $66.47M+6.4% | $62.49M+9.9% | $56.87M+31.2% | |
| U.S. | $502.1M-0.9% | $506.81M+12.7% | $449.86M-1.2% | $455.25M+17.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
